Project Details
Description
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
| Status | Finished |
|---|---|
| Effective start/end date | 27/11/12 → 31/07/20 |
Collaborative partners
- Hoffmann-La Roche Inc. (lead)
- Abu Dhabi Health Services Company
- Tawam Hospital
Keywords
- Neoplasms by Site
- Neoplasms
- Breast Diseases
- Skin Diseases
- Breast Neoplasms
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Molecular Mechanisms of Pharmacological Action
- Immunotoxins
- Immunoconjugates
- Immunologic Factors
- Physiological Effects of Drugs
- Trastuzumab
- Ado-Trastuzumab Emtansine
- Maytansine
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.